There is always the possibility that AGS aren't the only ones selling. Imagine what Heathgate and AGS could get if they both decided to sell B4M.
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress